Results 11 to 20 of about 5,494 (193)
Is Aducanumab for LMICs? Promises and Challenges [PDF]
Brain Sciences, 2021 Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer’s disease by the United States Food and Drug Administration (U.S. FDA).
Illangage P. C. Gunawardena +2 more
doaj +5 more sources
Drugs, 2021 Aducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid β. It has been co-developed by Biogen and Eisai under license from Neurimmune for the treatment of Alzheimer's disease.
Sohita Dhillon (4873375)
openaire +3 more sources
International Journal of Medical Science and Clinical Research Studies, 2022 Aducanumab (brand name Aduhelm) is the first FDA-approved, pharmacologic treatment for Alzheimer’s disease (AD) but many uncertainties remain regarding both efficacy and safety. Of paramount concern are associated adverse effects including cerebral edema and hemorrhage which prompted a post-approval study.
Asia Filatov, MD +1 more
openaire +3 more sources
Making the Case for the Accelerated Withdrawal of Aducanumab [PDF]
Journal of Alzheimer's Disease, 2022 U.S. Food and Drug Administration–s (FDA) approval of aducanumab (Aduhelm® in the US) as a treatment for mild cognitive impairment of the Alzheimer type and Alzheimer–s disease has raised such major concerns about efficacy, safety, FDA processes, and regulatory capture that Biogen–s license to market this biologic should be immediately withdrawn ...
Peter J, Whitehouse, Vikas, Saini
openaire +3 more sources
Cost Effectiveness and Resource Allocation, 2023 Background Alzheimer's Disease (AD), the most common type of dementia, is a chronic, progressive, and neurodegenerative brain discomfort that causes the be damage to brain cells.
Vahit Yigit +2 more
doaj +2 more sources
A Bayesian perspective on Biogen's aducanumab trial [PDF]
Alzheimer's & Dementia, 2022 AbstractThis perspective is a companion to a recent editorial on the use of Bayesian analysis in clinical research. We aim to introduce and highlight the relevance and advantages that Bayesian inference offers to clinical trials using the data on the amyloid antibody aducanumab presented at a Food and Drug Administration hearing in November 2020 as an ...
A.G.M. Temp (Anna) +6 more
openaire +7 more sources
Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab [PDF]
Canadian Geriatrics Journal, 2021 Alzheimer’s disease is a major cause of morbidity and mortality. Currently, there are no disease-modifying pharmacotherapies for this condition. Aducanumab, an amyloid beta-directed monoclonal antibody that targets aggregated forms of amyloid-beta in the
Howard Chertkow +16 more
doaj +2 more sources
Under-Represented Populations Left Out of Alzheimer’s Disease Treatment with Aducanumab: Commentary on Ethics [PDF]
Journal of Alzheimer's Disease Reports, 2022 Despite controversy about the efficacy and safety of aducanumab, the FDA’s fast-tracking of this medicine is truly historic. However, structural problems leading to socioeconomic disparities and systemic racism in science, healthcare, and society have ...
Sanjana P. Padala, Brandon C. Yarns
doaj +2 more sources
Aducanumab for the treatment of Alzheimer's disease
Drugs of Today, 2022 Alzheimer's disease (AD) is the most frequent neurodegenerative condition, the most common cause of dementia, and a leading cause of disability and death globally. Mounting evidence supported accumulation of amyloid β (Aβ) as the primary cause of AD pathology and sprouted a number of candidate treatments engaging Aβ from its production to its clearance,
M. Tagliapietra, Tagliapietra, Matteo
openaire +4 more sources
Aducanumab in Alzheimer’s Disease: A Critical Update
Current Medicinal Chemistry: Alzheimer's disease (AD) is a complex neurological disorder that results in cognitive decline. The incidence rates of AD have been increasing, particularly among individuals 60 years of age or older. In June 2021, the US FDA approved aducanumab, the first humanized monoclonal antibody, as a potential therapeutic option for AD.
Sumel, Ashique +10 more
openaire +3 more sources